Biotech Strategy Blog

Commentary on Science, Innovation & New Products

Posts tagged ‘Biotech Marketing Strategy’

Follow 2012 BIO CEO Investor Conference news on twitter #BIOCEO2012

By on February 13, 2012

New York Skyline from Empire State 300x168 Follow 2012 BIO CEO Investor Conference news on twitter #BIOCEO2012 The 2012 BIO CEO & Investor conference starts today in New York.

The meeting from February 13-14 is being held at the landmark Waldorf-Astoria hotel.

I’m looking forward to seeing some of the iconic hotel features such as the 1893 lobby clock originally produced for the Chicago World Fair.

With Wall Street analysts and investors in mind, the main focus of the 14th annual conference is on publicly traded biotechnology companies.

I expect that a number of the corporate presentations will be webcast, but if you are unable to be in NYC, you can follow the #BIOCEO2012 twitter conversation below:

This is a preview of Follow 2012 BIO CEO Investor Conference news on twitter #BIOCEO2012. Read the full post

Leave a comment

Biotech Strategy Blog now available on Kindle

By on October 17, 2011

For those readers who would like to access Biotech Strategy Blog on their Kindle, this is a quick post to let you know it is now available on the Amazon Kindle Store for $0.99/month.  You can also continue to read it for free on the web.

Biotech Strategy Blog Amazon Kindle Store 1024x372 Biotech Strategy Blog now available on KindleOf course, after Amazon takes its cut there is a (very) small royalty fee that ends up coming my way, so I have vested self-interest in promoting this.  However, it’s not something I anticipate getting rich from!

In a world of multi-channel marketing, it is good to try out new ideas that may make it easier for people to access content and information.

This is a preview of Biotech Strategy Blog now available on Kindle. Read the full post

Leave a comment

BioPharm America 2011 Biotech Partnering Conference #BPA11

By on September 7, 2011

BioPharm America 2011 Banner BioPharm America 2011 Biotech Partnering Conference #BPA11

A conference I regretably will not be at, but would have like to have attended is BioPharm America 2011 – 4th International Biotechnology Partnering Conference that is taking place in Boston from today until this Friday, September 9th.

The program overview suggests that it will be an interesting meeting with sessions on personalized medicine, business development and strategy and partnering. On friday there’s a briefing on Regenerative Medicine and Cell Therapy: The Road to Commercialization. If like me, you are unable to attend, you can follow the conversation on twitter using the hashtag #BPA11 (nice and short!).  I noticed there’s already some excellent live tweeting from the event. I’ve added an aggregator below to make it easier to follow or catch up on the news. Just click on the play button to see the tweets:  

Permanent link to this post (138 words, 1 image, estimated 33 secs reading time)
Leave a comment

BIO 2011 International Convention Video Review #BIO2011

By on July 1, 2011

Although I had to leave BIO 2011 early due to illness, I did shoot some video during the time I was at the meeting, and have now put this together into a short 2 minute video that you can watch below.

This post wraps up my coverage of the 2011 BIO international convention in Washington DC. Next week, I’ll be writing more about innovative science and new products in the pipeline that have caught my attention.

A happy holiday weekend to everyone in North America.

Permanent link to this post (86 words, estimated 21 secs reading time)
Leave a comment

Avastin for Breast Cancer is not Personalized Medicine

By on June 30, 2011

Bevacizumab (Avastin®) should be withdrawn for metastatic breast cancer. That is the unequivocal recommendation of the Oncology Drugs Advisory Committee (ODAC) yesterday.

Despite the passionate patient advocacy in favor of continued approval, withdrawal is the right decision and it is hard to see the FDA overruling ODAC, given the safety issues such as bowel perforations and relative lack of efficacy.  The patient advocacy at this week’s public hearing was fundamentally biased, those who died early and who received no treatment benefit are not alive to stand up and share their experiences.

This is a preview of Avastin for Breast Cancer is not Personalized Medicine. Read the full post

Leave a comment

BIO 2011 The face of Biotech Social Media #BIO2011

By on June 28, 2011

BIO 2011 Tweetup Old Dominion Brewhouse 300x169 BIO 2011 The face of Biotech Social Media #BIO2011The most enjoyable part of Day 1 of BIO 2011 for me was the unofficial tweetup at the Old Dominion Brewhouse.  Who are the people I have been interacting with on Twitter? Some have twitter handles close to their name, others like me are more cryptic. So at a tweetup it’s common to introduce yourself through the language of twitter, “I’m @3NT.”

Meeting up with someone you have had twitter conversations is like meeting up with a penpal (for those who can remember the days when we still wrote letters and didn’t have email, twitter or facebook). In many ways you already know each other and have common interests, so the conversation is easy.  Putting a name to a face is fun.

This is a preview of BIO 2011 The face of Biotech Social Media #BIO2011. Read the full post

Leave a comment

BIO 2011: Challenge of innovation in the biotechnology industry

By on June 22, 2011

White House Washington DC BIO 2011 Convention © Pieter Droppert 300x225 BIO 2011: Challenge of innovation in the biotechnology industryOne of the sessions at BIO 2011 in Washington DC that I hope to make if my travel plans permit, is the Monday afternoon session on “What is the Future for Innovative Medicines in Our Industry’s Pipeline?”

The June issue of Nature Reviews “Drug Discovery” attempts to answer this question by looking back at what happened to the R&D projects involving 28,000 compounds investigated since 1990.

Fabio Pammolli and colleagues analyzed the Pharmaceutical Industry Database (PhID) maintained by the IMT (Institutions, Markets, Technologies) in Lucca, Italy.

In their Drug Discovery article entitled “The productivity crisis in pharmaceutical R&D,” they reach a number of conclusions, some of which are:

This is a preview of BIO 2011: Challenge of innovation in the biotechnology industry. Read the full post

Leave a comment

BIO 2011: Ernst & Young Global Biotechnology Report 2011

By on June 20, 2011

One of the “Super Sessions” at the forthcoming 2011 Biotechnology Industry Organization (BIO) international convention is a presentation of the highlights of Ernst & Young’s 25th Annual Biotechnology Industry Report.

The 97 page report, available online, offers a useful summary of metrics around financing, deals and sector performance.

As the report notes, one of the key issues that biotech companies continue to face is access to funding in order to sustain innovation.  Many biotechnology executives I spoke to at the recent American Society of Clinical Oncology (ASCO) meeting in Chicago confirmed how difficult access to capital remained.

This is a preview of BIO 2011: Ernst & Young Global Biotechnology Report 2011. Read the full post

Leave a comment

BIO 2011: my top 10 sessions at the BIO International convention in Washington DC

By on June 18, 2011

BIO 2011 International Convention Washington DC BIO 2011: my top 10 sessions at the BIO International convention in Washington DC

I am excited to be attending, for the first time, the Biotechnology Industry Organization (BIO) international convention that takes place in Washington DC in just over a week’s time from Monday June 27 to Thursday, June 30th.

This meeting has something for everyone interested in the biotechnology industry whether it be deal making, partnering, licensing, drug discovery or personalized medicine. There are 16 specialized tracks where industry experts provide insight and best practices.

In addition, there are numerous networking and social events plus an exhibit hall that showcases the world’s biotech regions and how they are promoting innovation.

This is a preview of BIO 2011: my top 10 sessions at the BIO International convention in Washington DC. Read the full post

1 Comment